Briacell Historical Income Statement

BCTX Stock  USD 0.62  0.03  4.62%   
Historical analysis of Briacell Therapeutics income statement accounts such as Interest Expense of 0.0, Other Operating Expenses of 34.4 M or Total Operating Expenses of 34.4 M can show how well Briacell Therapeutics Corp performed in making a profits. Evaluating Briacell Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Briacell Therapeutics's future profits or losses.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Briacell Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Briacell Therapeutics is a good buy for the upcoming year.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Briacell Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

About Briacell Income Statement Analysis

Briacell Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Briacell Therapeutics shareholders. The income statement also shows Briacell investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Briacell Therapeutics Income Statement Chart

At this time, Briacell Therapeutics' Depreciation And Amortization is fairly stable compared to the past year. Other Operating Expenses is likely to rise to about 34.4 M in 2024, whereas Interest Expense is likely to drop 0.00 in 2024.

Depreciation And Amortization

The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.
Most accounts from Briacell Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Briacell Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Briacell Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
At this time, Briacell Therapeutics' Depreciation And Amortization is fairly stable compared to the past year. Other Operating Expenses is likely to rise to about 34.4 M in 2024, whereas Interest Expense is likely to drop 0.00 in 2024.

Briacell Therapeutics income statement Correlations

0.88-0.85-0.16-0.160.87-0.13-0.20.57-0.140.950.940.050.31-0.081.0-0.970.970.92
0.88-0.94-0.4-0.391.0-0.41-0.310.74-0.460.90.970.20.64-0.330.87-0.880.880.83
-0.85-0.940.520.52-0.940.550.34-0.880.6-0.89-0.970.12-0.670.51-0.830.83-0.83-0.79
-0.16-0.40.521.0-0.410.830.26-0.620.74-0.17-0.420.28-0.870.84-0.140.06-0.05-0.04
-0.16-0.390.521.0-0.410.830.25-0.620.74-0.17-0.420.28-0.870.84-0.140.05-0.05-0.04
0.871.0-0.94-0.41-0.41-0.44-0.290.74-0.490.90.960.190.65-0.330.85-0.880.880.83
-0.13-0.410.550.830.83-0.44-0.07-0.680.96-0.12-0.410.3-0.840.83-0.10.07-0.07-0.06
-0.2-0.310.340.260.25-0.29-0.07-0.490.09-0.44-0.290.12-0.240.34-0.210.19-0.19-0.19
0.570.74-0.88-0.62-0.620.74-0.68-0.49-0.790.670.78-0.370.72-0.780.56-0.520.530.49
-0.14-0.460.60.740.74-0.490.960.09-0.79-0.2-0.440.3-0.830.86-0.110.11-0.11-0.09
0.950.9-0.89-0.17-0.170.9-0.12-0.440.67-0.20.930.020.33-0.130.94-0.960.960.91
0.940.97-0.97-0.42-0.420.96-0.41-0.290.78-0.440.930.00.58-0.360.93-0.910.910.86
0.050.20.120.280.280.190.30.12-0.370.30.020.00.040.450.06-0.120.120.12
0.310.64-0.67-0.87-0.870.65-0.84-0.240.72-0.830.330.580.04-0.820.3-0.240.240.24
-0.08-0.330.510.840.84-0.330.830.34-0.780.86-0.13-0.360.45-0.82-0.08-0.040.040.05
1.00.87-0.83-0.14-0.140.85-0.1-0.210.56-0.110.940.930.060.3-0.08-0.960.960.91
-0.97-0.880.830.060.05-0.880.070.19-0.520.11-0.96-0.91-0.12-0.24-0.04-0.96-1.0-0.96
0.970.88-0.83-0.05-0.050.88-0.07-0.190.53-0.110.960.910.120.240.040.96-1.00.94
0.920.83-0.79-0.04-0.040.83-0.06-0.190.49-0.090.910.860.120.240.050.91-0.960.94
Click cells to compare fundamentals

Briacell Therapeutics Account Relationship Matchups

Briacell Therapeutics income statement Accounts

201920202021202220232024 (projected)
Depreciation And Amortization15.3K15.3K15.3K15.3K82.6K86.7K
Other Operating Expenses1.4M(3.7M)(3.4K)23.3M32.8M34.4M
Operating Income1.4M3.7M(15.3M)(23.3M)(32.8M)(31.2M)
Ebit1.4M(8.7M)(15.1M)(30.7M)(4.9M)(4.6M)
Ebitda1.4M(8.7M)(15.1M)(30.7M)(4.8M)(4.5M)
Total Operating Expenses(1.4M)(3.7M)(3.4K)23.3M32.7M34.4M
Net Income1.4M(2.9M)(11.6M)(20.3M)(4.8M)(4.6M)
Income Tax Expense(72.3K)6.6M30.7K(152.6K)62.9K59.7K
Selling General Administrative1.4M(3.7M)7.3M7.9M6.2M6.5M
Income Before Tax1.4M3.7M(11.5M)(20.3M)(4.8M)(5.0M)
Total Other Income Expense Net(72.3K)(6.8M)3.7M3.0M28.0M29.4M
Research Development2.2M1.3M8.0M15.3M26.8M28.1M
Net Interest Income(36.2K)(42.9K)(11.5M)891.2K288.0K302.4K
Interest Income512.633.1K136.7K891.2K288.0K186.2K
Net Income From Continuing Ops(4.9M)(428.3K)(15.3M)(20.3M)(4.9M)(5.2M)
Reconciled Depreciation18.7K15.3K15.3K15.3K83.9K88.1K
Net Income Applicable To Common Shares(5.8M)(4.9M)(428.3K)(26.8M)(24.2M)(22.9M)
Gross Profit(14.0K)(15.6K)(15.1K)(15.5K)(82.6K)(78.5K)
Cost Of Revenue14.0K15.6K15.1K15.5K82.6K86.7K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Briacell Stock Analysis

When running Briacell Therapeutics' price analysis, check to measure Briacell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Briacell Therapeutics is operating at the current time. Most of Briacell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Briacell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Briacell Therapeutics' price. Additionally, you may evaluate how the addition of Briacell Therapeutics to your portfolios can decrease your overall portfolio volatility.